Capecitabine and Xeroderma - a phase IV clinical study of FDA data

Summary:

Xeroderma is reported as a side effect among people who take Capecitabine (capecitabine), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Fluorouracil, and have Colorectal cancer metastatic.

The phase IV clinical study analyzes which people have Xeroderma when taking Capecitabine. It is created by eHealthMe based on reports of 59,451 people who have side effects when taking Capecitabine from the FDA, and is updated regularly.

What is Capecitabine?

Capecitabine has active ingredients of capecitabine. eHealthMe is studying from 59,495 Capecitabine users. Check the latest studies of Capecitabine.

What is Xeroderma?

Xeroderma (dry skin include itching and red, cracked or flaky skin) is found to be associated with 43 drugs and 294 conditions by eHealthMe. Check the latest studies of Xeroderma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

59,451 people reported to have side effects when taking Capecitabine.
Among them, 15 people (0.03%) have Xeroderma.

Among these 15 people:

How long have people been on Capecitabine when they have Xeroderma? *

What is the gender of people who have Xeroderma when taking Capecitabine? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Xeroderma when taking Capecitabine? *

What are other drugs people take besides Capecitabine? *

What are other side effects people have besides Xeroderma? *

Complex Regional Pain Syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet)): 7 people, 46.67%
Anaemia (lack of blood): 7 people, 46.67%
Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 7 people, 46.67%
Dermatitis Acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis): 7 people, 46.67%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 6 people, 40.00%
Diarrhea: 5 people, 33.33%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 3 people, 20.00%
Neuropathy Peripheral (surface nerve damage): 3 people, 20.00%
Rashes (redness): 3 people, 20.00%
Hypokalemia (low potassium): 3 people, 20.00%

What are the existing conditions these people have? *

Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 8 people, 53.33%
Breast Cancer: 3 people, 20.00%
Metastases To Bone (cancer spreads to bone): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Capecitabine and have Xeroderma?

- Check whether Xeroderma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Capecitabine:

Capecitabine (59,495 reports)

Xeroderma treatments and more:

Xeroderma (438 reports)

Browse all side effects of Capecitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Xeroderma:

Xeroderma (43 drugs)

Browse all the conditions that are associated with Xeroderma:

Xeroderma (294 conditions)

Related publications that referenced our studies

Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Capecitabine) and Capecitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.